Drugs · acquisition-cost intelligence
Mixed Salts of a Single-Entity Amphetamine Product
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate· ingredient dextroamphetamine· AMPHETAMINE ASPARTATE MONOHYDRATE 12.5 mg/1; AMPHETAMINE SULFATE 12.5 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 3.125 mg/1; AMPHETAMINE SULFATE 3.125 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 6.25 mg/1; AMPHETAMINE SULFATE 6.25 mg/1; AMPHETAMINE ASPARTATE MONOHYDRATE 9.375 mg/1; AMPHETAMINE SULFATE 9.375 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$8.51
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other dextroamphetamine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Adderall | $0.25990 | −$8.25 |
| Zenzedi | $0.42657 | −$8.09 |
| Adderall XR | $0.54992 | −$7.96 |
| PROCENTRA | $1.11 | −$7.40 |
| DEXEDRINE SPANSULE | $1.34 | −$7.18 |
| XELSTRYM | $16.26 | +$7.75 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.